Edition:
United Kingdom

AstraZeneca PLC (AZN.L)

AZN.L on London Stock Exchange

4,784.00GBp
8 Dec 2017
Change (% chg)

79.00 (+1.68%)
Prev Close
4,705.00
Open
4,705.50
Day's High
4,796.50
Day's Low
4,672.00
Volume
2,762,973
Avg. Vol
2,436,202
52-wk High
5,585.07
52-wk Low
4,134.50

Chart for

About

AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on discovery and development of products, which are then manufactured, marketed and sold. The Company focuses on three main therapy areas: Oncology, Cardiovascular & Metabolic Disease (CVMD) and Respiratory, while selectively pursuing therapies in... (more)

Overall

Beta: 1.04
Market Cap(Mil.): £65,514.78
Shares Outstanding(Mil.): 1,265.91
Dividend: 68.90
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 31.14 16.44
EPS (TTM): -- -- --
ROI: -- 14.86 10.62
ROE: -- 16.28 14.20

BRIEF-Astrazeneca Says Phase IV Ascent Trial Meets Primary Endpoints

* PHASE IV ASCENT TRIAL MEETS PRIMARY ENDPOINTS IN COPD PATIENTS WITH CARDIOVASCULAR RISK FACTORS‍​ Source text for Eikon: Further company coverage:

04 Dec 2017

BRIEF-G1 Therapeutics And AstraZeneca Enter Clinical Trial Collaboration In Non-Small Cell Lung Cancer

* G1 THERAPEUTICS AND ASTRAZENECA ENTER CLINICAL TRIAL COLLABORATION IN NON-SMALL CELL LUNG CANCER

28 Nov 2017

BRIEF-Astrazeneca Plc says EMA accepts Tagrisso submission for 1st-line nsclc

* ‍EUROPEAN MEDICINES AGENCY ACCEPTS REGULATORY SUBMISSION FOR TAGRISSO IN 1ST-LINE EGFR-MUTATED NON-SMALL CELL LUNG CANCER​ Source text for Eikon: Further company coverage: (Bangalore.newsroom@thomsonreuters.com)

28 Nov 2017

AstraZeneca steps up China push with new drug joint venture

LONDON Drugmaker AstraZeneca plans to turbo-charge its already substantial Chinese business through a new drug development joint venture with a state-backed private equity fund.

27 Nov 2017

BRIEF-Astrazeneca makes regulatory submission for tagrisso in 1st-line egfr-mutated non-small cell lung cancer in Japan​

* ‍ASTRAZENECA MAKES REGULATORY SUBMISSION FOR TAGRISSO IN 1ST-LINE EGFR-MUTATED NON-SMALL CELL LUNG CANCER IN JAPAN​ Source text for Eikon: Further company coverage: (bangalore.newsroom@thomsonreuters.com)

27 Nov 2017

AstraZeneca steps up China push with new drug joint venture

LONDON Drugmaker AstraZeneca plans to turbo-charge its already substantial Chinese business through a new drug development joint venture with a state-backed private equity fund.

27 Nov 2017

AstraZeneca steps up China push with new drug joint venture

LONDON, Nov 27 Drugmaker AstraZeneca plans to turbo-charge its already substantial Chinese business through a new drug development joint venture with a state-backed private equity fund.

27 Nov 2017

Roche win boosts case for adding chemo to cancer immunotherapy

LONDON Cancer doctors struggling to work out the best way to use modern immunotherapy drugs now have further evidence of the benefits of adding them to chemotherapy, despite earlier scepticism.

20 Nov 2017

Spanish stocks - Factors to watch on Friday

The following Spanish stocks may be affected by newspaper reports and other factors on Friday. Reuters has not verified the newspaper reports, and cannot vouch for their accuracy:

17 Nov 2017

BRIEF-Almirall announces achievement of $80 mln sales-related milestones from agreement with Astrazeneca‍​

* ANNOUNCES ACHIEVEMENT OF $80 MILLION SALES-RELATED MILESTONES FROM AGREEMENT WITH ASTRAZENECA‍​ Source text for Eikon:

17 Nov 2017

Earnings vs. Estimates